• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovo Nordisk

Novo Nordisk

Page 2 of 9
CVS strikes a deal to offer Wegovy at a discount
Health
CVS strikes a deal to offer Wegovy at a discount
By Chris MorrisMay 1, 2025
Novo Nordisk slides on pressure from Lilly’s pill study
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By Marthe Fourcade and BloombergApril 22, 2025
LArs Freurgaard Jorgensen and Ursula von der Leyen pictured among Danish business leaders in 2024.
Health
Europe’s pharma titans confront von der Leyen with threat to yank $113 billion from EU and relocate to U.S. as Trump plans ‘major’ tariffs
By Ryan HoggApril 9, 2025
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
Magazine
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By Vivienne WaltMarch 31, 2025
SAP topples Novo to become Europe’s most-valuable listed company
Finance
SAP topples Novo to become Europe’s most-valuable listed company
By Henry Ren and BloombergMarch 24, 2025
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Retail
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
By Paula Doenecke, Naomi Kresge and BloombergMarch 12, 2025
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Finance
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By Chris MorrisMarch 7, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership
As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
By Ryan HoggFebruary 4, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
DeepSeek and Ozempic are complicating decarbonization forecasts
Environment
DeepSeek and Ozempic are complicating decarbonization forecasts
By Aaron Clark and BloombergJanuary 31, 2025
A cautionary tale that Europe can’t afford to ignore
Magazine
A cautionary tale that Europe can’t afford to ignore
By Alex Wood MortonJanuary 31, 2025
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Economy
How Scott Bessent used financial engineering to finance the $2 trillion deficit while leaving it untouched—and created a $1.45 trillion shortfallplaceholder alt text
By Eva RoytburgAugust 8, 2026
Real Estate
Meet the 33-year-old CEO betting on boomers chasing their grandkids—and millennials selling their first houseplaceholder alt text
By Nick LichtenbergAugust 8, 2026
Real Estate
The tables have turned: Florida and Texas are the biggest losers in the housing market as Ohio emerges a surprise winnerplaceholder alt text
By Sydney LakeAugust 8, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.